Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)

M. Slomovitz, Brian; John Weroha, S.; Deng, Wei; Sook Chon, Hye; Podder, Vivek; Tilley Jenkins Vogel, Mary; Backes, Floor; D. Thomas, Eric; Chen, Lee-may; Tenney, Meaghan; N. Westin, Shannon; Jennifer Markham, Merry; S. Miller, David; I. Edelson, Mitchell; Y. Muller, Carolyn; J. Callahan, Michael; L. Holman, Laura; Rebecca Liu, J.; Teplinsky, Eleonora; A. Kamat, Aparna; S. Guy, Michael; Chern, Jing‐Yi; Lea, Jayanthi; Murphy, Martina; M. Choong, Grace; Diaz Moore, Elena; Alvarez, Edwin; H. Rodgers, William; M. O’Malley, David; J. Copeland, Larry; J. Herzog, Thomas; L. Coleman, Robert; M. Gershenson, David

doi:10.1200/jco-25-01348

Public

Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)

Published in Journal of Clinical Oncology • Dec 12, 2025

Authors:

Brian M. Slomovitz

S. John Weroha

Wei Deng

Abstract

PURPOSE: Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kin...

Subject

Medicine

Letrozole

Oncology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!